Summit Corporation Plc

Summit Therapeutics Plc

Stephen Paul Wren

Peter David Johnson

Colin Richard Dorgan

Graham Michael Wynne

Olivier De Moor

Richard Storer

Francis Xavier Wilson

Lauren Jayne Sudlow

Renate Maria Van Well

Paul Damien Price

Gary Nugent

Richard Joseph Pye

Richard Vickers

Richard John Vickers

Robert Clarkson

Renate Van Well

Jonathon Mark Tinsley

Alexander Charles Weymouth-Wilson

Collin Richard Dorgan

Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by,

[object Object]

Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by,

There are disclosed compound of Formula (1): A, A, Aand Awhich may be the same or different, represent N or CR, X is a divalent group selected from O, S(O), C&#x2550;W, NR, NC(&#x2550;O)Rand CRR, W is O, S, NR, Y is N or CR, one of R, R, R, R, Rand NRrepresents -L-R, in which L is a single bond or a linker group, additionally, R, R-R, which may be the same or different, independently represent hydrogen or a substituent and Rrepresents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO, NRR, in which Rand R, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of Rand Rmay represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A-Aeach represent CR, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CRR, Rand R, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia. 

Treatment of Duchenne muscular dystrophy

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. 

Drug combinations for the treatment of duchenne muscular dystrophy

Provided is a process for the preparation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl) benzo[d] oxazole useful in the treatment of Duchenne muscular dystrophy.

Treatment of duchenne muscular dystrophy

Growing community of inventors

Abingdon, United Kingdom

Stephen Paul Wren